News >

Ibrutinib Associated With Superior QoL in MCL Compared With Temsirolimus

Jason Harris
Published: Wednesday, Jul 12, 2017

lymphoma
Phase III results from the RAY trial showed that patients with mantle cell lymphoma (MCL) treated with ibrutinib (Imbruvica) had superior quality of life (QoL) compared with patients treated with temsirolimus. The findings were published online in Leukemia & Lymphoma.

Researchers found that EQ-5D-5L values did not return to baseline levels in the temsirolimus group, and were consistently lower than those in the ibrutinib group at any time point up to cycle 14.
Hess G, Rule S, Jurczak W, et al. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus [published online May 30, 2017]. Leuk Lymphoma. doi: 10.1080/10428194.2017.1326034.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x